Green Cross, LG Life Sciences Team Up To Sell Osteoarthritis Drug To Compete With Pfizer's Celebrex
This article was originally published in PharmAsia News
Executive Summary
SEOUL - Korea vaccine leader Green Cross Corp. and LG Life Sciences Ltd. have teamed up to co-promote Shinbaro, a first-line osteoarthritis treatment developed by Green Cross that could compete against Pfizer Inc.'s Celebrex
You may also be interested in...
Green Cross Concludes Takeover Deal Of Innocell; Looks To Overseas Markets For Growth
Korea’s Green Cross to continue development of Innocell’s Immuncell-LC cancer cell therapy after becoming the major shareholder of the troubled company.
Korea Tries To Buffer Heavy Price Cuts With R&D Incentives, But Local And Global Pharma Up In Arms
TOKYO - South Korea's Ministry of Health and Welfare announced this week dual measures to drastically cut drug prices, while also committing to support Korea's innovation-focused companies through tax credits and preferential pricing
Green Cross Is Latest Korean Pharma To Struggle Under Regulatory Headwinds
SEOUL - Green Cross Corp. has continued a trend among Korean pharma companies by posting relatively sluggish second quarter results